- Home
- Publications
- Publication Search
- Publication Details
Title
T Cell–Activating Bispecific Antibodies in Cancer Therapy
Authors
Keywords
-
Journal
JOURNAL OF IMMUNOLOGY
Volume 203, Issue 3, Pages 585-592
Publisher
The American Association of Immunologists
Online
2019-07-23
DOI
10.4049/jimmunol.1900496
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm
- (2019) Naveen Pemmaraju et al. NEW ENGLAND JOURNAL OF MEDICINE
- A review of bispecific antibodies and antibody constructs in oncology and clinical challenges
- (2019) Frans V. Suurs et al. PHARMACOLOGY & THERAPEUTICS
- A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM/CD3 T-cell engager (BiTE®) antibody construct, in patients with refractory solid tumors
- (2018) Maxim Kebenko et al. OncoImmunology
- Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome–Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study
- (2017) Giovanni Martinelli et al. JOURNAL OF CLINICAL ONCOLOGY
- Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL
- (2017) J Duell et al. LEUKEMIA
- Next generation antibody drugs: pursuit of the 'high-hanging fruit'
- (2017) Paul J. Carter et al. NATURE REVIEWS DRUG DISCOVERY
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2017) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
- (2017) Hagop Kantarjian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Engineering of Anti-CD133 Trispecific Molecule Capable of Inducing NK Expansion and Driving Antibody-Dependent Cell-Mediated Cytotoxicity
- (2017) Jörg U. Schmohl et al. Cancer Research and Treatment
- Resistance to anti-CD19/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking
- (2016) Friederike Braig et al. BLOOD
- A bispecific protein rG7S-MICA recruits natural killer cells and enhances NKG2D-mediated immunosurveillance against hepatocellular carcinoma
- (2016) Tong Wang et al. CANCER LETTERS
- IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function
- (2016) D. A. Vallera et al. CLINICAL CANCER RESEARCH
- Phase 1 Dose Escalation Study of MEDI-565, a Bispecific T-Cell Engager that Targets Human Carcinoembryonic Antigen, in Patients With Advanced Gastrointestinal Adenocarcinomas
- (2016) Michael Pishvaian et al. Clinical Colorectal Cancer
- Half-life extended biotherapeutics
- (2016) Roland E. Kontermann EXPERT OPINION ON BIOLOGICAL THERAPY
- Immunotherapeutic implications of IL-6 blockade for cytokine storm
- (2016) Toshio Tanaka et al. Immunotherapy
- Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia
- (2016) Arend von Stackelberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study
- (2016) Maria-Elisabeth Goebeler et al. JOURNAL OF CLINICAL ONCOLOGY
- A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo
- (2016) S Hipp et al. LEUKEMIA
- CD123-Engager T Cells as a Novel Immunotherapeutic for Acute Myeloid Leukemia
- (2016) Challice L Bonifant et al. MOLECULAR THERAPY
- T-cell responses against CD19+ pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80/CD86 on leukemic blasts
- (2016) Judith Feucht et al. Oncotarget
- Targeting CD123 in acute myeloid leukemia using a T-cell-directed dual-affinity retargeting platform
- (2015) M. Al-Hussaini et al. BLOOD
- A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma
- (2015) A. Rothe et al. BLOOD
- Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment
- (2015) G. Zugmaier et al. BLOOD
- Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19/CD3-bispecific T cell engager antibody blinatumomab
- (2015) Thomas Köhnke et al. Journal of Hematology & Oncology
- B7H6-Specific Bispecific T Cell Engagers Lead to Tumor Elimination and Host Antitumor Immunity
- (2015) Ming-Ru Wu et al. JOURNAL OF IMMUNOLOGY
- Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
- (2015) Max S Topp et al. LANCET ONCOLOGY
- Alternative molecular formats and therapeutic applications for bispecific antibodies
- (2015) Christoph Spiess et al. MOLECULAR IMMUNOLOGY
- Anti-CD20/CD3 T cell–dependent bispecific antibody for the treatment of B cell malignancies
- (2015) Liping L. Sun et al. Science Translational Medicine
- Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy
- (2015) E. Sotillo et al. Cancer Discovery
- Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma
- (2014) Y.-T. Tai et al. BLOOD
- Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients
- (2014) A. E. Frankel et al. BLOOD
- Bispecific T-cell engagers for cancer immunotherapy
- (2014) Amelia M Huehls et al. IMMUNOLOGY AND CELL BIOLOGY
- A Novel Method Using Blinatumomab for Efficient, Clinical-Grade Expansion of Polyclonal T Cells for Adoptive Immunotherapy
- (2014) Josée Golay et al. JOURNAL OF IMMUNOLOGY
- B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma
- (2013) R. O. Carpenter et al. CLINICAL CANCER RESEARCH
- Preclinical In Vivo Modeling of Cytokine Release Syndrome Induced by ErbB-Retargeted Human T Cells: Identifying a Window of Therapeutic Opportunity?
- (2013) S. J. C. van der Stegen et al. JOURNAL OF IMMUNOLOGY
- CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia
- (2013) R. J. Brentjens et al. Science Translational Medicine
- Antigen-Specific T-Cell Activation Independently of the MHC: Chimeric Antigen Receptor-Redirected T Cells
- (2013) Markus Chmielewski et al. Frontiers in Immunology
- Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab
- (2012) M. Klinger et al. BLOOD
- Novel Humanized and Highly Efficient Bispecific Antibodies Mediate Killing of Prostate Stem Cell Antigen-Expressing Tumor Cells by CD8+ and CD4+ T Cells
- (2012) A. Feldmann et al. JOURNAL OF IMMUNOLOGY
- Strategies for extended serum half-life of protein therapeutics
- (2011) Roland E Kontermann CURRENT OPINION IN BIOTECHNOLOGY
- Delivery of NKG2D Ligand Using an Anti-HER2 Antibody-NKG2D Ligand Fusion Protein Results in an Enhanced Innate and Adaptive Antitumor Response
- (2010) H.-M. Cho et al. CANCER RESEARCH
- The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial
- (2010) Markus M. Heiss et al. INTERNATIONAL JOURNAL OF CANCER
- Efficient Inhibition of Human B-cell Lymphoma in SCID Mice by Synergistic Antitumor Effect of Human 4-1BB Ligand/Anti-CD20 Fusion Proteins and Anti-CD3/Anti-CD20 Diabodies
- (2010) Rong Liu et al. JOURNAL OF IMMUNOTHERAPY
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Highly Efficient Elimination of Colorectal Tumor-Initiating Cells by an EpCAM/CD3-Bispecific Antibody Engaging Human T Cells
- (2010) Ines Herrmann et al. PLoS One
- Bispecific T-Cell Engaging Antibodies for Cancer Therapy
- (2009) P. A. Baeuerle et al. CANCER RESEARCH
- Biodistribution of a Bispecific Single-chain Diabody and Its Half-life Extended Derivatives
- (2009) Roland Stork et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Examination of the contributions of size and avidity to the neutralization mechanisms of the anti-HIV antibodies b12 and 4E10
- (2009) J. S. Klein et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started